Delcath Systems (DCTH) to Release Earnings on Thursday

Delcath Systems (NASDAQ:DCTH) is expected to post its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $20.3540 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 8:30 AM ET.

Delcath Systems Trading Up 2.6%

DCTH stock opened at $10.21 on Thursday. The stock has a market capitalization of $360.52 million, a PE ratio of 1,021.00 and a beta of 0.37. Delcath Systems has a 12-month low of $8.12 and a 12-month high of $18.23. The stock’s 50 day simple moving average is $10.02 and its 200 day simple moving average is $10.22.

Delcath Systems announced that its board has approved a stock repurchase plan on Thursday, November 20th that allows the company to buyback $25.00 million in outstanding shares. This buyback authorization allows the company to purchase up to 8.6% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Analyst Ratings Changes

A number of brokerages have recently commented on DCTH. BTIG Research reiterated a “buy” rating and issued a $23.00 price target on shares of Delcath Systems in a research note on Tuesday, November 4th. Weiss Ratings restated a “sell (d+)” rating on shares of Delcath Systems in a report on Monday, December 29th. Stephens decreased their target price on shares of Delcath Systems from $25.00 to $18.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of Delcath Systems in a report on Friday, January 9th. Finally, Wall Street Zen raised Delcath Systems from a “hold” rating to a “buy” rating in a report on Saturday, January 10th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Delcath Systems currently has a consensus rating of “Moderate Buy” and an average target price of $22.40.

Institutional Investors Weigh In On Delcath Systems

A number of hedge funds have recently modified their holdings of the business. Nantahala Capital Management LLC bought a new position in Delcath Systems in the 3rd quarter worth $7,164,000. Marshall Wace LLP purchased a new stake in Delcath Systems in the second quarter worth about $6,572,000. Rosalind Advisors Inc. raised its stake in shares of Delcath Systems by 13.8% in the second quarter. Rosalind Advisors Inc. now owns 3,300,389 shares of the company’s stock worth $44,885,000 after buying an additional 400,000 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Delcath Systems by 116.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 587,678 shares of the company’s stock worth $5,936,000 after buying an additional 315,583 shares during the period. Finally, Lane Generational LLC bought a new position in shares of Delcath Systems in the fourth quarter worth about $1,997,000. Institutional investors own 61.12% of the company’s stock.

Delcath Systems Company Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.